Related Experiment Video
Updated: Mar 23, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.6K
Striving for optimal bronchodilation: focus on olodaterol.
Cristoforo Incorvaia1, Marcello Montagni2, Elena Makri1
1Allergy/Pulmonary Rehabilitation, Istituti Clinici di Perfezionamento Hospital, Milan, Italy.
Summary
Olodaterol, a very-long-acting beta2-agonist, offers 24-hour bronchodilation for chronic obstructive pulmonary disease (COPD). It improves lung function and quality of life with a safety profile comparable to placebo.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Trials
Background:
- Beta2-agonists are essential bronchodilators for obstructive respiratory diseases.
- Very-long-acting beta2-agonists enable once-daily administration.
- Olodaterol represents a novel very-long-acting beta2-agonist.
Purpose of the Study:
- To evaluate the efficacy and safety of olodaterol in patients with chronic obstructive pulmonary disease (COPD).
- To assess olodaterol's impact on lung function, clinical outcomes, and quality of life.
- To compare olodaterol's effects with existing treatments like formoterol.
Main Methods:
- Controlled clinical trials involving patients with moderate to very severe COPD.
- Assessment of lung function parameters.
- Evaluation of clinical outcomes, quality of life, and adverse events.
Main Results:
- Olodaterol demonstrated rapid onset of action and 24-hour bronchodilation.
- It improved lung function and quality of life in COPD patients.
- Olodaterol showed comparable efficacy to formoterol twice daily but superior quality of life benefits.
- Safety profile was favorable, with adverse events, including cardiac events, similar to placebo.
Conclusions:
- Olodaterol is an effective and safe very-long-acting beta2-agonist for COPD management.
- It offers significant improvements in lung function and quality of life.
- The Respimat(®) device enhances olodaterol's therapeutic effectiveness.
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
2.0K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.0K
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
01:23Inhaled Medications
975
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
975
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.5K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.5K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K